Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment.

IF 3.6 3区医学 Q2 ONCOLOGY American journal of cancer research Pub Date : 2024-09-15 eCollection Date: 2024-01-01 DOI:10.62347/JWHA6355

Shujuan Ma, Yan Zhou, Dandan Ma, Xiaowei Qi, Jun Jiang

{"title":"Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment.","authors":"Shujuan Ma, Yan Zhou, Dandan Ma, Xiaowei Qi, Jun Jiang","doi":"10.62347/JWHA6355","DOIUrl":null,"url":null,"abstract":"<p><p>HER2-positive breast cancer is highly aggressive, with a significant risk of recurrence and metastasis, leading to a poor prognosis. While most early-stage HER2-positive breast cancer patients benefit from combining trastuzumab monoclonal antibody with chemotherapy, the therapeutic response to various drug combinations varies across the HER2+ patient population. Therefore, predicting the prognosis and treatment response of HER2+ breast cancer patients to specific regimens is crucial for selecting appropriate precision individualized therapies. HER2DX is the first genomic tool designed to guide the treatment of HER2+ breast cancer patients. The three scores provided by HER2DX inform the entire treatment process, including predicting survival outcomes, recurrence, metastasis, and treatment responses like Pathological Complete Response Rate (pCR). It offers recommendations on follow-up intervals, treatment plans, and the duration of drug therapy. This review examines the literature and analyzes studies applying HER2DX to guide the comprehensive treatment and predict prognosis in HER2+ breast cancer patients, aiming to promote the widespread use of HER2DX in individualized treatment.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 9","pages":"4218-4235"},"PeriodicalIF":3.6000,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11477836/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/JWHA6355","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

HER2-positive breast cancer is highly aggressive, with a significant risk of recurrence and metastasis, leading to a poor prognosis. While most early-stage HER2-positive breast cancer patients benefit from combining trastuzumab monoclonal antibody with chemotherapy, the therapeutic response to various drug combinations varies across the HER2+ patient population. Therefore, predicting the prognosis and treatment response of HER2+ breast cancer patients to specific regimens is crucial for selecting appropriate precision individualized therapies. HER2DX is the first genomic tool designed to guide the treatment of HER2+ breast cancer patients. The three scores provided by HER2DX inform the entire treatment process, including predicting survival outcomes, recurrence, metastasis, and treatment responses like Pathological Complete Response Rate (pCR). It offers recommendations on follow-up intervals, treatment plans, and the duration of drug therapy. This review examines the literature and analyzes studies applying HER2DX to guide the comprehensive treatment and predict prognosis in HER2+ breast cancer patients, aiming to promote the widespread use of HER2DX in individualized treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

HER2DX 基因组检测在 HER2+ 乳腺癌治疗中的应用与挑战。

HER2阳性乳腺癌具有高度侵袭性，复发和转移的风险很大，导致预后不良。虽然大多数早期 HER2 阳性乳腺癌患者都能从曲妥珠单抗联合化疗中获益，但不同的 HER2+ 患者群体对各种药物组合的治疗反应却各不相同。因此，预测HER2+乳腺癌患者的预后和对特定方案的治疗反应对于选择适当的精准个体化疗法至关重要。HER2DX 是首个旨在指导 HER2+ 乳腺癌患者治疗的基因组工具。HER2DX 提供的三项评分可为整个治疗过程提供信息，包括预测生存结果、复发、转移和治疗反应，如病理完全反应率 (pCR)。它对随访间隔、治疗计划和药物治疗的持续时间提出了建议。本综述对应用 HER2DX 指导综合治疗和预测 HER2+ 乳腺癌患者预后的文献进行了研究分析，旨在促进 HER2DX 在个体化治疗中的广泛应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.